Compare RCON & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCON | VNRX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2M | 31.9M |
| IPO Year | 2008 | 2012 |
| Metric | RCON | VNRX |
|---|---|---|
| Price | $0.93 | $0.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 93.9K | ★ 16.0M |
| Earning Date | 03-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,430,788.00 | $1,727,384.00 |
| Revenue This Year | N/A | $479.89 |
| Revenue Next Year | N/A | $536.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.04 |
| 52 Week Low | $0.75 | $0.17 |
| 52 Week High | $7.16 | $0.94 |
| Indicator | RCON | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 37.71 |
| Support Level | N/A | N/A |
| Resistance Level | $1.46 | $0.32 |
| Average True Range (ATR) | 0.13 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 39.24 | 12.84 |
Recon Technology Ltd provides automation systems, industrial equipment, and support services tailored for the oil and gas industry in China. The company's business spans key segments such as automation products and software, equipment and accessories, oilfield environmental protection, and platform outsourcing services. It generates the majority of its revenue by providing integrated automation services to Chinese petroleum companies at oilfields. Its key products and services include pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system. The company's operations are centered on servicing upstream clients throughout China, with some broader industrial automation solutions.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.